Abstract
The present invention relates to a method for predicting the risk of developing Insulin resistance and/or type 2 diabetes and/or metabolic syndrome for a subject, based on the levels of DLK1. A determined level above a reference level is indicative of said subject being at risk of developing Insulin resistance and/or type 2 diabetes and/or metabolic syndrome and a determined level equal to or below the reference level is indicative of said subject not being currently at risk of developing Insulin resistance and/or type 2 diabetes and/or metabolic syndrome.
Original language | English |
---|---|
IPC | C12Q 1/ 6883 A I |
Patent number | EP3657176 |
Country/Territory | Denmark |
Priority date | 23/11/2018 |
Priority number | EP20180207954 |
Publication status | Published - 27. May 2020 |